With the backdrop of news on Monday that Sunshine Biopharma, Inc. (OTCBB:SBFM) will be presenting new scientific data at the American Association for Cancer Research Meeting in Chicago, IL (to be held on March 31 – April 4, 2012), shares of the junior biotech surged a cool 100% to close Monday’s trading at 50 cents each. Read More

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that it was featured Friday, January 20th on the front page of the Boston Business Journal print edition. Owned by American City Business Journals, the Boston Business Journal is available in both print and online versions and reaches hundreds of thousands of subscribers each month. Read More

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide corporate updates on Kevetrin™, its novel drug in development for drug-resistant cancers, and KM-133, its compound being developed as a revolutionary psoriasis indication. Read More

Popular biotechnology website BioTuesdays.com published an article this morning on Cellceutix Corporation (OTCBB: CTIX) discussing the recent developments and significant potential of Cellceutix as a result of its cancer drug, Kevetrin, and other drugs in its pipeline.  The article, titled “Cellceutix’s potential breakthrough in cancer research,” spends time noting the “Holy Grail” p53 connection Read More

Cellceutix Corporation (OTCBB:CTIX) has filed its Investigational New Drug (IND) application for Kevetrin™, a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating Read More

Cellceutix Updates Shareholders; Answers Questions About Clinical Trials for Novel Cancer Drug
Cellceutix Corporation (OTCQB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide shareholders with the following update. The Company’s accomplishments in cancer have garnered much attention Read More

Human xenograft mouse models have shown Kevetrin, the Cellceutix Corporation (OTCQB:CTIX) drug in development as a new cancer therapy, to slow tumor growth and reduce tumor volume as released by Cellceutix today. The news release also addresses updates to the Investigational New Drug application to include the prostate cancer research and clinical protocol from the hosting hospital. To learn more, read the Cellceutix press release and get a CTIX stock quote.

Cellceutix Corporation (OTCQB:CTIX) announced this morning that they have signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer. Read More

The CEO of Cellceutix Corporation (OTCQB: CTIX), a preclinical cancer, anti-inflammatory and autism drug developer says his company’s leading drug candidate, Kevetrin, is a new class of chemistry in medicine which has proven to this point to restore p53 (also known as the “Guardian Angel” gene ) back to a normal status so it can do its job as master regulator and see to it that the cancer cells are destroyed without damaging any DNA. Read More

Cellceutix Corporation (OTCQB:CTIX) issued big news this morning that they have received the “thumbs-up” from one of the world’s leading cancer research centers to host the Company’s clinical trials for Kevetrin™.  Cellceutix is developing (and posting strong pre-clinical results) Kevetrin™ as an indication for a multitude of cancers including drug-resistant, pancreatic, lung, leukemia and breast cancers.  The cancer center was not disclosed, but there are several industry-leading centers in the east/northeast United States.  U.S. News recently released their list of the top cancer hospitals in the U.S.  The Top 5 included Memorial Sloan-Kettering in New York, NY; Johns Hopkins in Baltimore, MD; and Dana-Farber/Brigham and Women’s in Boston, which will have investors wondering which center will be hosting the trials Read More